Biopharmaceutical company Ferring Pharmaceuticals Inc revealed on Monday the availability of CLENPIQ (sodium picosulfate, magnesium oxide and anhydrous citric acid) oral solution for cleansing of the colon in adults undergoing a colonoscopy by prescription in the US.

Colorectal cancer is reportedlythe third most common cancer and second leading cause of cancer death in the US. Colonoscopies can help reduce the incidence of colorectal cancer and deaths associated with this disease.

The company said CLENPIQ is the only US Food and Drug Administration (FDA) approved prescription bowel prep that comes "ready-to-drink". It is a ready-to-drink, low volume bowel prep with cranberry-flavor. It is a dual-acting, combination of sodium picosulfate, a stimulant laxative and magnesium oxide and anhydrous citric acid, which forms magnesium citrate, an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults.

According to the company, CLENPIQ has established efficacy and safety based on clinical trials with another oral formulation of sodium picosulfate, magnesium oxide and anhydrous citric acid. About 84% of patients achieved successful cleansing of the overall colon (primary endpoint) and 90% achieved successful cleansing of the ascending colon (secondary endpoint).

In conjunction with the trial, the primary efficacy endpoint was the proportion of patients with successful cleansing of the overall colon defined as "excellent" or "good" using the Aronchick scale, which is scored before washing of the colon, concluded the company.